Cargando…

Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models

Lymphomas are cancers deriving from lymphocytes, arising preferentially in secondary lymphoid organs, and represent the 6th cancer worldwide and the most frequent blood cancer. The majority of B cell Non-Hodgkin lymphomas (B-NHL) develop from germinal center (GC) experienced mature B cells. GCs are...

Descripción completa

Detalles Bibliográficos
Autores principales: Mossadegh-Keller, Noushin, Brisou, Gabriel, Beyou, Alicia, Nadel, Bertrand, Roulland, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323519/
https://www.ncbi.nlm.nih.gov/pubmed/34335584
http://dx.doi.org/10.3389/fimmu.2021.683597
_version_ 1783731257645989888
author Mossadegh-Keller, Noushin
Brisou, Gabriel
Beyou, Alicia
Nadel, Bertrand
Roulland, Sandrine
author_facet Mossadegh-Keller, Noushin
Brisou, Gabriel
Beyou, Alicia
Nadel, Bertrand
Roulland, Sandrine
author_sort Mossadegh-Keller, Noushin
collection PubMed
description Lymphomas are cancers deriving from lymphocytes, arising preferentially in secondary lymphoid organs, and represent the 6th cancer worldwide and the most frequent blood cancer. The majority of B cell Non-Hodgkin lymphomas (B-NHL) develop from germinal center (GC) experienced mature B cells. GCs are transient structures that form in lymphoid organs in response to antigen exposure of naive B cells, and where B cell receptor (BCR) affinity maturation occurs to promote B cell differentiation into memory B and plasma cells producing high-affinity antibodies. Genomic instability associated with the somatic hypermutation (SHM) and class-switch recombination (CSR) processes during GC transit enhance susceptibility to malignant transformation. Most B cell differentiation steps in the GC are at the origin of frequent B cell malignant entities, namely Follicular Lymphoma (FL) and GCB diffuse large B cell lymphomas (GCB-DLBCL). Over the past decade, large sequencing efforts have provided a great boost in the identification of candidate oncogenes and tumor suppressors involved in FL and DLBCL oncogenesis. Mouse models have been instrumental to accurately mimic in vivo lymphoma-specific mutations and interrogate their normal function in the GC context and their oncogenic function leading to lymphoma onset. The limited access of biopsies during the initiating steps of the disease, the cellular and (epi)genetic heterogeneity of individual tumors across and within patients linked to perturbed dynamics of GC ecosystems make the development of genetically engineered mouse models crucial to decipher lymphomagenesis and disease progression and eventually to test the effects of novel targeted therapies. In this review, we provide an overview of some of the important genetically engineered mouse models that have been developed to recapitulate lymphoma-associated (epi)genetic alterations of two frequent GC-derived lymphoma entities: FL and GCB-DLCBL and describe how those mouse models have improved our knowledge of the molecular processes supporting GC B cell transformation.
format Online
Article
Text
id pubmed-8323519
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83235192021-07-31 Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models Mossadegh-Keller, Noushin Brisou, Gabriel Beyou, Alicia Nadel, Bertrand Roulland, Sandrine Front Immunol Immunology Lymphomas are cancers deriving from lymphocytes, arising preferentially in secondary lymphoid organs, and represent the 6th cancer worldwide and the most frequent blood cancer. The majority of B cell Non-Hodgkin lymphomas (B-NHL) develop from germinal center (GC) experienced mature B cells. GCs are transient structures that form in lymphoid organs in response to antigen exposure of naive B cells, and where B cell receptor (BCR) affinity maturation occurs to promote B cell differentiation into memory B and plasma cells producing high-affinity antibodies. Genomic instability associated with the somatic hypermutation (SHM) and class-switch recombination (CSR) processes during GC transit enhance susceptibility to malignant transformation. Most B cell differentiation steps in the GC are at the origin of frequent B cell malignant entities, namely Follicular Lymphoma (FL) and GCB diffuse large B cell lymphomas (GCB-DLBCL). Over the past decade, large sequencing efforts have provided a great boost in the identification of candidate oncogenes and tumor suppressors involved in FL and DLBCL oncogenesis. Mouse models have been instrumental to accurately mimic in vivo lymphoma-specific mutations and interrogate their normal function in the GC context and their oncogenic function leading to lymphoma onset. The limited access of biopsies during the initiating steps of the disease, the cellular and (epi)genetic heterogeneity of individual tumors across and within patients linked to perturbed dynamics of GC ecosystems make the development of genetically engineered mouse models crucial to decipher lymphomagenesis and disease progression and eventually to test the effects of novel targeted therapies. In this review, we provide an overview of some of the important genetically engineered mouse models that have been developed to recapitulate lymphoma-associated (epi)genetic alterations of two frequent GC-derived lymphoma entities: FL and GCB-DLCBL and describe how those mouse models have improved our knowledge of the molecular processes supporting GC B cell transformation. Frontiers Media S.A. 2021-07-16 /pmc/articles/PMC8323519/ /pubmed/34335584 http://dx.doi.org/10.3389/fimmu.2021.683597 Text en Copyright © 2021 Mossadegh-Keller, Brisou, Beyou, Nadel and Roulland https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Mossadegh-Keller, Noushin
Brisou, Gabriel
Beyou, Alicia
Nadel, Bertrand
Roulland, Sandrine
Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models
title Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models
title_full Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models
title_fullStr Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models
title_full_unstemmed Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models
title_short Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models
title_sort human b lymphomas reveal their secrets through genetic mouse models
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323519/
https://www.ncbi.nlm.nih.gov/pubmed/34335584
http://dx.doi.org/10.3389/fimmu.2021.683597
work_keys_str_mv AT mossadeghkellernoushin humanblymphomasrevealtheirsecretsthroughgeneticmousemodels
AT brisougabriel humanblymphomasrevealtheirsecretsthroughgeneticmousemodels
AT beyoualicia humanblymphomasrevealtheirsecretsthroughgeneticmousemodels
AT nadelbertrand humanblymphomasrevealtheirsecretsthroughgeneticmousemodels
AT roullandsandrine humanblymphomasrevealtheirsecretsthroughgeneticmousemodels